AstraZeneca Gets Planning OK for New Global Cambridge R&D Facility
AstraZeneca reports that the Cambridge City Council has granted planning permission for the company's new global R&D center and corporate headquarters in Cambridge, the United Kingdom. The purpose-built facility will be located on the Cambridge Biomedical Campus and will be home to approximately 2,000 employees.
The Cambridge site will bring together AstraZeneca's small-molecule and biologics research and development activity. It will become the company's largest center for oncology research, as well as housing scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation, and autoimmune diseases and conditions of the central nervous system. The site will also be home to a joint research center, which will see Medical Research Council (MRC)–supported researchers working side-by-side with AstraZeneca's high-throughput screening group. The MRC is a is publicly funded government agency responsible for coordinating and funding medical research in the United Kingdom.
In advance of the new site becoming operational at the end of 2016, more than 400 AstraZeneca staff have already relocated to interim facilities in Cambridge, at the Melbourn Science Park, Cambridge Science Park and Granta Park. This is in addition to the approximately 500 staff already located at the company's MedImmune facility at Granta Park.